Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis

Ads

You May Also Like

Cesca Announces Closing of $5.5 Million Public Offering

RANCHO CORDOVA, Calif., May 18, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...